404: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY BASELINE LIVER FUNCTION FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB (T) PLUS DURVALUMAB (D) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) | Publicación